Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Lab21 and IntegraGen Partner

Published: Tuesday, March 05, 2013
Last Updated: Tuesday, March 05, 2013
Bookmark and Share
Lab21 Limited has entered into an agreement with IntegraGen to develop a microRNA assay for colorectal cancer designed to further improve patient outcomes.

Under the agreement, Lab21 will develop a CE marked assay, using its proprietary SPARQ™ PCR technology, to detect expression levels of a microRNA biomarker called hsa-mir-31-3p, which was discovered and patented by IntegraGen and its academic partners. Early research with this biomarker has shown that it may predict response to EGFR inhibitor therapy in KRAS-wild type patients who have metastatic colorectal cancer. Financial details were not disclosed.

Most patients with metastatic colorectal cancer are currently screened and stratified by determining mutations in the KRAS gene. Approximately 40% of these patients carry a KRAS mutation and are not candidates for EGFR inhibitor therapy. Of the approximately 60% of patients who do not carry a KRAS mutation (ie KRAS wild type) and who are eligible for EGFR inhibitor therapy, effectiveness is still only 50-60%. MicroRNA expression testing may provide a further level of stratification and thus aid clinicians to identify KRAS wild type patients most likely to respond to treatment: improving outcomes, avoiding adverse reaction and saving money in the healthcare system.

Graham Mullis, CEO of Lab21, commented: “We are delighted to enter into this assay development agreement with IntegraGen. Lab21’s experience in developing molecular diagnostics in the oncology and infectious disease settings is increasingly being recognised by major diagnostic manufacturers and pharmaceutical partners. The combination of our highly efficient assay development capability, regulatory and manufacturing know-how is actively being sought by developers of novel diagnostics, such as IntegraGen, who need partners to commercialise their biomarkers, including a route to market.”

Bernard Courtieu, CEO of IntegraGen, added: “We are pleased to be working with Lab21 to progress this biomarker towards commercialisation in Europe. On the basis of good clinical results and regulatory approval we hope to have a CE Marked kit available based on Lab21’s technology by early 2014. With over 500,000 patients diagnosed with metastatic colorectal cancer annually on a global basis, there is a large market potential for an assay based on this biomarker.”

Following development of the assay, Lab21 and IntegraGen will explore other opportunities for partnerships relative to the manufacturing and commercialisation of this novel oncology biomarker.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Novacyt, Lab21 to Combine in Stock-For-Stock Transaction
On completing the transaction, Lab21 will become a 100% subsidiary of Novacyt, and the combined group will be rebranded.
Wednesday, May 28, 2014
Lab21 and IntegraGen Partner to Develop New Colorectal Cancer Diagnostic
Lab21 to develop a CE marked assay to detect expression levels of a microRNA biomarker.
Tuesday, February 26, 2013
Lab21 Partners with Major Pharmaceutical Company to Develop New Companion Diagnostic Assay
Agreement allows Lab21 to develop, manufacture and distribute a new companion diagnostic assay for the detection of specific mutations in colorectal cancer samples to select patients for the partner's therapeutic monoclonal antibody.
Tuesday, June 26, 2012
Lab21 Expands Companion Diagnostic Cancer Testing Service Internationally
Lab21 now offer its K-RAS gene mutation and its epidermal growth factor receptor mutation testing services to its international customers.
Friday, July 18, 2008
Lab21 Expands Cancer Gene Testing Service
Lab21 has now added an epidermal growth factor receptor mutation test to its existing range.
Friday, June 27, 2008
Lab21 Launches Cancer Gene Testing Service
Lab21 is providing a test for analysis of the K-ras gene that plays an important role in cell growth regulation and the proliferation of cancer cells.
Friday, January 25, 2008
Scientific News
Benchtop Automation Trends
Gain a better understanding of current interest in and future deployment of benchtop automated systems.
Higher Frequency of Huntington's Disease Mutations Discovered
University of Aberdeen study shows that the gene change that causes Huntington's disease is much more common than previously thought.
Revealing the Genetic Causes of Bowel Cancer
A landmark study has given the most detailed picture yet of the genetics of bowel cancer — the UK's fourth most common cancer.
The Epigenetic Influences of Chronic Pain
Researchers at Drexel University College of Medicine are aiming to identify new molecular mechanisms involved in pain.
Fighting Resistant Blood Cancer Cells
Biologists present new findings on chronic myeloid leukemia and possible therapeutic approaches.
Tumor Cells Develop Predictable Characteristics
Scientists have discovered that cancer cells at the edge of a tumor that are close to the surrounding environment are predictably different from the cells within the interior of the tumor.
Mothers Obesity Could be Passed on in mtDNA
Obesity can predispose offspring in multiple generations to metabolic problems.
New Imaging Method Reveals Nanoscale Details about DNA
Enhancement to super-resolution microscopy shows orientation of individual molecules, providing a new window into DNA’s structure and dynamics.
Genetic Research Can Significantly Improve Drug Development
With drug development costs topping $1.2bn (£850 million) to get a single treatment to the point it can be sold and used in the clinic, could genetic analysis save hundreds of millions of dollars?
Naked Mole Rat Exhibits “Extraordinary” Cancer Resistance
Scientists are getting closer to understanding the anti-cancer mechanism of the naked mole rat by making induced pluripotent stem cells.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!